BIO-TECHNE Corp Lessee, Operating Lease, Liability, to be Paid, Year Five
BIO-TECHNE Corp (TECH) had Lessee, Operating Lease, Liability, to be Paid, Year Five of $11.38 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive · last filed 2026-08-24
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Five $11.38M.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Five $13.44M.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Five $12.97M.
- 2023-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Five $12.48M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Five |
|---|---|
| 2026-06-30 | $11.38M 10-K · filed 2026-08-24 |
| 2025-06-30 | $13.44M 10-K · filed 2025-08-22 |
| 2024-06-30 | $12.97M 10-K · filed 2024-08-22 |
| 2023-06-30 | $12.48M 10-K · filed 2023-08-23 |
| 2022-06-30 | $8.32M 10-K · filed 2022-08-24 |
| 2021-06-30 | $10.12M 10-K · filed 2021-08-25 |
| 2020-06-30 | $9.39M 10-K · filed 2020-08-26 |
| 2020-03-31 | $8.32M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $8.30M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $8.17M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |